One Nasal Spray to Fight COVID, Flu, Pneumonia, Allergies

A Single Spray, Many Enemies

Scientists at Stanford Medicine have developed a nasal spray vaccine that — in mouse experiments — protected against an extraordinary range of respiratory threats: SARS-CoV-2, other coronaviruses, hospital-acquired bacteria, and even common allergens. The results, published on February 19 in the journal Science, represent a fundamental departure from more than two centuries of vaccine design.

Traditional vaccines train the immune system to recognize a specific pathogen. This one does something far more ambitious: it reprograms the innate immune cells of the lungs themselves, effectively putting the respiratory tract on permanent high alert against whatever threat arrives.

Breaking With 230 Years of Vaccine Logic

The vaccine formula, designated GLA-3M-052-LS+OVA, does not mimic any particular virus or bacterium. Instead, it mimics the molecular signals that immune cells use to communicate with each other during an active infection. It also contains a harmless egg protein (ovalbumin) that draws T cells into the lungs, where they sustain the heightened innate response for weeks to months.

"The lung immune system is so ready and so alert that it can launch adaptive responses in as little as three days," said Bali Pulendran, the study's senior author and a professor of pathology and microbiology at Stanford. In unvaccinated mice, a comparable adaptive response takes roughly two weeks — a window in which severe illness or death can occur.

Pulendran called the results "a universal vaccine against diverse respiratory threats."

What the Mouse Data Shows

In controlled experiments, mice that received three intranasal doses of the vaccine showed:

• A 700-fold reduction in lung virus levels following SARS-CoV-2 exposure
• Complete survival during viral challenges that killed unvaccinated controls
• Protection lasting at least three months against multiple coronavirus strains
• Resistance to Staphylococcus aureus and Acinetobacter baumannii, two bacteria responsible for dangerous hospital-acquired infections
• Reduced allergic responses to house dust mites, with airways remaining clear

The Immune Mechanism Behind the Breakthrough

The key insight driving the research was that T cells recruited to the lungs as part of the adaptive immune response were sending ongoing cytokine signals to innate immune cells — keeping them active far longer than normal. The vaccine artificially replicates those signals, using toll-like receptor stimulants to maintain the innate system's readiness for months rather than the usual few days.

This dual activation — innate cells primed for rapid response, T cells sustaining the alert — creates what the researchers described as a "double whammy" defense against pathogens.

Cautious Optimism From Outside Experts

Not everyone is convinced the approach will translate seamlessly to humans. Florian Krammer, a vaccinologist at Mount Sinai, cautioned that the innate immune system may have inherent limits on how much it can be enhanced — a concern relevant to safety as well as efficacy. Nonetheless, Krammer supported moving forward with human testing.

The Road to Human Trials

The Stanford team plans to begin Phase I safety trials and estimates a five-to-seven-year timeline to potential commercial availability, contingent on adequate funding. Pulendran envisions a practical scenario in which a single fall nasal spray provides seasonal coverage against COVID-19, influenza, RSV, the common cold, bacterial pneumonia, and spring allergens — effectively replacing the multiple injections many people currently receive each year.

If the results hold in humans, the implications extend well beyond convenience. A broad-spectrum nasal vaccine could provide a critical first line of defense against future pandemic pathogens — including ones that do not yet exist.